## First-Line Antihypertensives in Diabetic Hypertension ### Clinical Context **Key Point:** In patients with type 2 diabetes and hypertension, the goals are: 1. Blood pressure control 2. Renal protection (slow progression of diabetic nephropathy) 3. Cardioprotection (reduce MI and stroke risk) 4. Avoid worsening glycemic control ### Appropriate First-Line Agents (Options 0, 1, 3) **Option 0 — Lisinopril (ACE Inhibitor):** - ✓ **First-line in diabetic hypertension** - Mechanism: blocks angiotensin II → reduces efferent arteriolar vasoconstriction - Result: ↓ glomerular hyperfiltration → ↓ proteinuria → slows CKD progression - Reduces cardiovascular events in diabetes - No adverse metabolic effects **Option 1 — Amlodipine (Calcium Channel Blocker):** - ✓ **Acceptable first-line option** - Effective BP control - Does NOT worsen glucose metabolism (unlike thiazides and beta-blockers) - Causes peripheral edema (common side effect, but not a contraindication) - Less renoprotective than ACE-I/ARB, but still safe **Option 3 — Losartan (ARB):** - ✓ **First-line in diabetic hypertension** - Mechanism: blocks AT1 receptors → same renal protection as ACE-I - Preferred if patient has ACE-I cough or angioedema - Reduces proteinuria and slows CKD progression - Cardioprotective in diabetes ### Inappropriate Agent (Option 2) — Immediate-Release Nifedipine **Warning:** Immediate-release (short-acting) nifedipine is **NOT recommended** as first-line therapy in hypertension, especially in diabetic patients, because: 1. **Unpredictable absorption** → erratic blood pressure control 2. **Reflex tachycardia** → increased sympathetic activation → increased myocardial oxygen demand 3. **Increased risk of myocardial infarction** — particularly in acute coronary syndromes (established in landmark trials) 4. **Increased cardiovascular mortality** when used in acute settings 5. **Sublingual administration** is associated with stroke risk **High-Yield:** The **NIFEDIPINE CONTROVERSY:** - ~~Immediate-release nifedipine~~ — NOT first-line (risk of MI, stroke) - ✓ **Extended-release (ER) nifedipine** — acceptable (smoother BP control, no reflex tachycardia) - ✓ **Other long-acting CCBs** (amlodipine, diltiazem ER) — preferred over IR nifedipine **Clinical Pearl:** In diabetic patients, the rapid, unpredictable vasodilation from IR nifedipine can trigger coronary steal and worsen myocardial perfusion, especially if there is underlying coronary artery disease. ## Comparison Table: First-Line Agents in Diabetic Hypertension | Agent | Class | Renal Protection | Metabolic Effect | Cardiovascular Protection | First-Line? | |---|---|---|---|---|---| | Lisinopril | ACE-I | ✓✓ (↓ proteinuria) | Neutral | ✓ (↓ MI, stroke) | ✓ YES | | Losartan | ARB | ✓✓ (↓ proteinuria) | Neutral | ✓ (↓ MI, stroke) | ✓ YES | | Amlodipine | CCB (ER) | ✓ (neutral) | Neutral | ✓ (safe) | ✓ YES | | IR Nifedipine | CCB (short-acting) | Neutral | Neutral | ✗ (↑ MI risk) | ✗ NO | | Hydrochlorothiazide | Thiazide | Neutral | ✗ (↑ glucose) | Neutral | ✗ Second-line | | Atenolol | Beta-blocker | Neutral | ✗ (↑ glucose) | Neutral | ✗ Second-line | [cite:Harrison 21e Ch 297; KD Tripathi 8e Ch 31]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.